A Phase II observational study of Haematopoietic Stem Cell Transplantation for highly active, treatment resistant MS
This trial is testing whether an autologous (self) haematopoietic stem cell transplant (AHSCT) for highly active, treatment resistant multiple sclerosis reduces MS disease activity over 5 years. The treatment involves: treatment, collection and freezing of stem cells from the patient’s blood; chemotherapy (BEAM-ATG) to destroy the immune system; reinfusion of the patient’s own stem cells. […]